BioAmber Inc. (NYSE:BIOA) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $0.46 and last traded at $0.46, with a volume of 370,070 shares traded. The stock had previously closed at $0.47.

A number of brokerages have weighed in on BIOA. ValuEngine cut shares of BioAmber from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 8th. Zacks Investment Research upgraded shares of BioAmber from a “sell” rating to a “hold” rating in a research report on Wednesday, July 26th. Finally, Cowen and Company set a $3.00 price target on shares of BioAmber and gave the company a “hold” rating in a research report on Monday, July 17th.

The company’s 50-day moving average is $1.79 and its 200-day moving average is $2.41. The firm’s market capitalization is $16.68 million.

BioAmber (NYSE:BIOA) last posted its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by $0.03. The business had revenue of $4.12 million for the quarter, compared to analyst estimates of $4.09 million. BioAmber had a negative return on equity of 56.55% and a negative net margin of 221.82%. On average, equities research analysts expect that BioAmber Inc. will post ($0.58) EPS for the current year.

Hedge funds have recently modified their holdings of the stock. NN Investment Partners Holdings N.V. purchased a new stake in shares of BioAmber during the first quarter valued at about $2,548,000. FMR LLC boosted its position in BioAmber by 18.7% in the first quarter. FMR LLC now owns 1,335,000 shares of the biotechnology company’s stock valued at $3,097,000 after buying an additional 210,000 shares during the period. Sabby Management LLC acquired a new position in BioAmber during the first quarter valued at approximately $3,388,000. Robecosam AG boosted its position in BioAmber by 3.1% in the first quarter. Robecosam AG now owns 825,000 shares of the biotechnology company’s stock valued at $1,898,000 after buying an additional 25,000 shares during the period. Finally, Vanguard Group Inc. boosted its position in BioAmber by 9.9% in the second quarter. Vanguard Group Inc. now owns 303,360 shares of the biotechnology company’s stock valued at $780,000 after buying an additional 27,278 shares during the period. 47.04% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “BioAmber Inc. (BIOA) Sets New 12-Month Low at $0.46” was originally reported by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/08/22/bioamber-inc-bioa-sets-new-12-month-low-at-0-46.html.

BioAmber Company Profile

BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.